Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 14/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trandolaprilat SCHEMBL156829 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL11076552 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL678354 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL5567196 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173132 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL683838 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173121 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL11286342 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL5794079 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173113 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1052 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| WO-2024263793-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2024-12-26 | — | — | WO | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| EP-3474836-B1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | REKIK RAOUF (TN) | 2024-01-17 | — | — | EP | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| CN-116234545-A | Composition of fixed dose SGLT-2 inhibitor and angiotensin converting enzyme inhibitor and application | 北京睿创康泰医药研究院有限公司 | 2023-06-06 | — | — | CN | claimed |
| US-11484513-B2 | Salbutamol-containing ophthalmic medicament | REKIK RAOUF (TN) | 2022-11-01 | — | — | US | claimed |
| EP-1778234-B2 | PIMOBENDAN TO BE USED FOR THE REDUCTION OF HEART SIZE IN MAMMALS SUFFERING FROM HEART FAILURE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2021-06-23 | — | — | EP | claimed |
| US-10537588-B2 | Use of pimobendan for the reduction of heart size in mammals suffering from heart failure | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2020-01-21 | — | — | US | claimed |
| CN-1384756-A | Pharmaceutical formulations and their use in the prevention of stroke, diabetes and/or congestive heart failure | AVENTIS PHARMA GMBH (DE) | 2002-12-11 | — | — | CN | claimed |
| CN-1368881-A | Use of inhibitors of renin-angiotensin systemin prevention of cardiovascular events | AVENTIS PHARMA GMBH (DE) | 2002-09-11 | — | — | CN | claimed |
| EP-1216038-A2 | USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM IN THE PREVENTION OF CARDIOVASCULAR EVENTS | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | claimed |
| EP-0876158-B1 | NOVEL MEDICAL USE OF AN ACE-INHIBITOR FOR TREATMENT OF DYSPEPTIC SYMPTOMS | PHARMACORE AB (SE) | 2002-06-12 | — | — | EP | claimed |
| EP-1212081-A2 | PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE | Aventis Pharma Deutschland GmbH (DE) | 2002-06-12 | — | — | EP | claimed |
| WO-2002003970-A2 | MATRIX CONTROLLED TRANSDERMAL SYSTEM FOR STABILE DERIVATIVES OF ACE INHIBITORS | HEXAL AG (DE) | 2002-01-17 | — | — | WO | claimed |
| WO-2001015673-A2 | PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-08 | — | — | WO | claimed |
| WO-2001015674-A2 | USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM IN THE PREVENTION OF CARDIOVASCULAR EVENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-08 | — | — | WO | claimed |
| US-5977159-A | Medical use of an ace-inhibitor for treatment of dyspeptic symptoms | ASTRA AKTIEBOLAG (SE) | 1999-11-02 | — | — | US | claimed |
| CN-1207685-A | Novel medical use of ACE-inhibitor for treatment of dyspeptic symptoms | ASTRA AB (SE) | 1999-02-10 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484513-B2 | Salbutamol-containing ophthalmic medicament | ADRB3, ADRB2, ADRB1 | ACE 667/4885MEN1 1105/4885KMT2A 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.